Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials

English version České info

Background:
It has been suggested that statins substantially reduce the risk of venous thromboembolic events. We sought to test this hypothesis by performing a meta-analysis of both published and unpublished results from randomised trials of statins.

Methods and Findings:
We searched MEDLINE, EMBASE, and Cochrane CENTRAL up to March 2012 for randomised controlled trials comparing statin with no statin, or comparing high dose versus standard dose statin, with 100 or more randomised participants and at least 6 months' follow-up. Investigators were contacted for unpublished information about venous thromboembolic events during follow-up. Twenty-two trials of statin versus control (105,759 participants) and seven trials of an intensive versus a standard dose statin regimen (40,594 participants) were included. In trials of statin versus control, allocation to statin therapy did not significantly reduce the risk of venous thromboembolic events (465 [0.9%] statin versus 521 [1.0%] control, odds ratio [OR] = 0.89, 95% CI 0.78–1.01, p = 0.08) with no evidence of heterogeneity between effects on deep vein thrombosis (266 versus 311, OR 0.85, 95% CI 0.72–1.01) and effects on pulmonary embolism (205 versus 222, OR 0.92, 95% CI 0.76–1.12). Exclusion of the trial result that provided the motivation for our meta-analysis (JUPITER) had little impact on the findings for venous thromboembolic events (431 [0.9%] versus 461 [1.0%], OR = 0.93 [95% CI 0.82–1.07], p = 0.32 among the other 21 trials). There was no evidence that higher dose statin therapy reduced the risk of venous thromboembolic events compared with standard dose statin therapy (198 [1.0%] versus 202 [1.0%], OR = 0.98, 95% CI 0.80–1.20, p = 0.87). Risk of bias overall was small but a certain degree of effect underestimation due to random error cannot be ruled out.

Please see later in the article for the Editors' Summary.

Conclusions:

The findings from this meta-analysis do not support the previous suggestion of a large protective effect of statins (or higher dose statins) on venous thromboembolic events. However, a more moderate reduction in risk up to about one-fifth cannot be ruled out.

Vyšlo v časopise: Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials. PLoS Med 9(9): e32767. doi:10.1371/journal.pmed.1001310
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001310

Souhrn

Please see later in the article for the Editors' Summary.

Zdroje

1. SilversteinMD, HeitJA, MohrDN, PettersonTM, O'FallonWM, et al. (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 158: 585–593.

2. HeitJA (2005) Venous thromboembolism: disease burden, outcomes and risk factors. J Thromb Haemost 3: 1611–1617.

3. NaessIA, ChristiansenSC, RomundstadP, CannegieterSC, RosendaalFR, et al. (2007) Incidence and mortality of venous thrombosis: a population-based study. J Thromb Haemost 5: 692–699.

4. Cholesterol Treatment Trialists' Collaboration (2005) Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 366: 1267–1278.

5. GlynnRJ, DanielsonE, FonsecaFAH, GenestJ, GottoAM, et al. (2009) A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med 360: 1851–1861.

6. GradyD, WengerNK, HerringtonD, KhanS, FurbergC, et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease: The Heart and Estrogen/progestin Replacement Study. Ann Intern Med 132: 689–696.

7. RayJG, MamdaniM, TsuyukiRT, AndersonDR, YeoEL, et al. (2001) Use of statins and the subsequent development of deep vein thrombosis. Arch Intern Med 161: 1405–1410.

8. PrandoniP, BiloraF, MarchioriA, BernardiE, PetrobelliF, et al. (2003) An association between atherosclerosis and venous thrombosis. N Engl J Med 348: 1435–1441.

9. SrensenHT, Horvath-PuhoE, PedersenL, BaronJA, PrandoniP (2007) Venous thromboembolism and subsequent hospitalisation due to acute arterial cardiovascular events: a 20-year cohort study. Lancet 370: 1773–1779.

10. AgenoW, BecattiniC, BrightonT, SelbyR, KamphuisenPW (2008) Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation 117: 93–102.

11. UndasA, Brummel-ZiedinsKE, MannKG (2005) Statins and blood coagulation. Arterioscler Thromb Vasc Biol 25: 287–294.

12. Sen-BanerjeeS, MirS, LinZ, HamikA, AtkinsGB, et al. (2005) Kruppel-like factor 2 as a novel mediator of statin effects in endothelial cells. Circulation 112: 720–726.

13. TehraniS, MobarrezF, AntovicA, SantessonP, LinsP-E, et al. (2010) Atorvastatin has antithrombotic effects in patients with type 1 diabetes and dyslipidemia. Thromb Res 126: e225–e231.

14. RamcharanAS, Van StralenKJ, SnoepJD, Mantel-TeeuwisseAK, RosendaalFR, et al. (2009) HMG-CoA reductase inhibitors, other lipid-lowering medication, antiplatelet therapy, and the risk of venous thrombosis. J Thromb Haemost 7: 514–520.

15. SerensenHT, Horvath-PuhoE, SogaardKK, ChristensenS, JohnsenSP, et al. (2009) Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost 7: 521–528.

16. IoannidisJPA (2005) Contradicted and initially stronger effects in highly cited clinical research. JAMA 294: 218–228.

17. EvansNS, GreenD (2009) ASH evidence-based guidelines: statins in the prevention of venous thromboembolism. ASH Education Program Book 2009: 273–274.

18. PerezA, BartholomewJR (2010) Interpreting The JUPITER Trial: statins can prevent VTE, but more study is needed. Cleve Clin J Med 77: 191–194.

19. KhemasuwanD, ChaeYK, GuptaS, CarpioA, YunJH, et al. (2011) Dose-related effect of statins in venous thrombosis risk reduction. Am J Med 124: 852–859.

20. RahimiK, EmbersonJ, McGaleP, MajoniW, MerhiM, et al. (2011) Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. BMJ 342: d1250.

21. (2011) Cochrane handbook for systematic reviews of interventions. Higgins JPT, Green S, editors. Version 5.1.0 (updated March 2011) London: The Cochrane Collaboration.

22. NissenSE (2005) Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) trial. Am J Cardiol 96: 61f–68f.

23. DoggenCJ, LemaitreRN, SmithNL, HeckbertSR, PsatyBM (2004) HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women. J Thromb Haemost 2: 700–701.

24. YusufS, PetoR, LewisJ, CollinsR, SleightP (1985) Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 27: 335–371.

25. R Development Core Team (2005) R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing.

26. FreemanD, RobertsonM, BrownEA, RumleyA, TobiasE, et al. (2011) Incident venous thromboembolic events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). BMC Geriatrics 11: 8.

27. DownsJR, ClearfieldM, WeisS, WhitneyE, ShapiroDR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279: 1615–1622.

28. (1998) Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 339: 1349–1357.

29. Heart Protection Study Collaborative Group (2002) MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7–22.

30. SeverPS, DahlofB, PoulterNR, WedelH, BeeversG, et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trials-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361: 1149–1158.

31. FellstromB, HoldaasH, JardineAG, HolmeI, NybergG, et al. (2004) Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 66: 1549–1555.

32. ColhounHM, BetteridgeDJ, DurringtonPN, HitmanGA, NeilHA, et al. (2004) Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364: 685–696.

33. AsselbergsFW, DiercksGFH, HillegeHL, Van BovenAJ, JanssenWMT, et al. (2004) Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110: 2809–2816.

34. KorenMJ, HunninghakeDB (2004) Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The ALLIANCE study. J Am Coll Cardiol 44: 1772–1779.

35. WannerC, KraneV, MarzW, OlschewskiM, MannJF, et al. (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248.

36. CowellSJ, NewbyDE, PrescottRJ, BloomfieldP, ReidJ, et al. (2005) A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352: 2389–2397.

37. NakamuraH, ArakawaK, ItakuraH, KitabatakeA, GotoY, et al. (2006) Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 368: 1155–1163.

38. KnoppRH, D'EmdenM, SmildeJG, PocockSJ (2006) Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN). Diabetes Care 29: 1478–1485.

39. AmarencoP, BogousslavskyJ, CallahanA3rd, GoldsteinLB, HennericiM, et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559.

40. KjekshusJ, ApetreiE, BarriosV, BohmM, ClelandJG, et al. (2007) Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357: 2248–2261.

41. SolaS, MirMQS, LerakisS, TandonN, KhanBV (2006) Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failure. J Am Coll Cardiol 47: 332–337.

42. (2008) GISSI-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372: 1231–1239.

43. CrouseJR3rd, RaichlenJS, RileyWA, EvansGW, PalmerMK, et al. (2007) Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 297: 1344–1353.

44. FeldmanHH, DoodyRS, KivipeltoM, SparksDL, WatersDD, et al. (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease. Neurology 74: 956–964.

45. ChanKL, TeoK, DumesnilJG, NiA, TamJ, et al. (2010) Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial. Circulation 121: 306–314.

46. FassettRG, RobertsonIK, BallMJ, GeraghtyDP, CoombesJS (2010) Effect of atorvastatin on kidney function in chronic kidney disease: a randomised double-blind placebo-controlled trial. Atherosclerosis 213: 218–224.

47. SmildeTJ, van WissenS, WollersheimH, TripMD, KasteleinJJ, et al. (2001) Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 357: 577–581.

48. De LemosJA, BlazingMA, WiviottSD, LewisEF, FoxKAA, et al. (2004) Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: Phase Z of the A to Z trial. JAMA 292: 1307–1316.

49. NissenSE, TuzcuEM, SchoenhagenP, BrownBG, GanzP, et al. (2004) Effect of Intensive Compared with Moderate Lipid-Lowering Therapy on Progression of Coronary Atherosclerosis: A Randomized Controlled Trial. JAMA 291: 1071–1080.

50. CannonCP, BraunwaldE, McCabeCH, RaderDJ, RouleauJL, et al. (2004) Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350: 1495–1504.

51. LaRosaJC, GrundySM, WatersDD, ShearC, BarterP, et al. (2005) Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 1425–1435.

52. PedersenTR, FaergemanO, KasteleinJJP, OlssonAG, TikkanenMJ, et al. (2005) High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. JAMA 294: 2437–2445.

53. (2010) SEARCH Collaborative Group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 376: 1658–1669.

54. CollinsR, MacMahonS (2001) Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials. Lancet 357: 373–380.

55. CollinsR, ArmitageJ (2002) High-risk elderly patients PROSPER from cholesterol-lowering therapy. Lancet 360: 1618–1619.

56. Baigent C, Peto R, Gray R, Collins R (2010) Large-scale randomized evidence: trials and meta-analyses of trials. Warrell DA, Cox TM, Firth JD, editors. Oxford textbook of medicine. 5th edition. Oxford: Oxford University Press.

57. CookDJ, GuyattGH, RyanG, CliftonJ, BuckinghamL, et al. (1993) Should unpublished data be included in meta-analyses? current convictions and controversies. JAMA 269: 2749–2753.

58. GrangerCB, VogelV, CummingsSR, HeldP, FiedorekF, et al. (2008) Do we need to adjudicate major clinical events? Clin Trials 5: 56–60.

59. PogueJ, WalterSD, YusufS (2009) Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. Clin Trials 6: 239–251.

60. SchwartzGG, ChaitmanBR, GoldbergerJJ, MessigM (2010) High-dose atorvastatin and risk of atrial fibrillation in patients with prior stroke or transient ischemic attack: Analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Am Heart J 161: 993–999.

61. Cholesterol Treatment Trialists' Collaboration (2010) Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681.